Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Eli Lilly & Co (LLY) and Ionis Pharmaceuticals (IONS)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Laboratories (ABT), Eli Lilly & Co (LLY) and Ionis Pharmaceuticals (IONS) with bullish sentiments.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abbott Laboratories (ABT)
Barclays analyst Matt Miksic maintained a Buy rating on Abbott Laboratories today and set a price target of $144.00. The company’s shares closed last Thursday at $95.47.
According to TipRanks.com, Miksic is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abbott Laboratories with a $131.71 average price target, a 35.6% upside from current levels. In a report released yesterday, TipRanks – DeepSeek also upgraded the stock to Buy with a $112.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Eli Lilly & Co (LLY)
In a report released today, Emily Field from Barclays maintained a Buy rating on Eli Lilly & Co, with a price target of $1350.00. The company’s shares closed last Thursday at $903.99.
According to TipRanks.com, Field is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $1247.71 average price target, implying a 36.9% upside from current levels. In a report issued on April 5, TipRanks – xAI also upgraded the stock to Buy with a $1038.00 price target.
Ionis Pharmaceuticals (IONS)
Barclays analyst Eliana Merle maintained a Buy rating on Ionis Pharmaceuticals today and set a price target of $106.00. The company’s shares closed last Thursday at $75.26.
According to TipRanks.com, Merle is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ionis Pharmaceuticals with a $100.25 average price target, which is a 31.2% upside from current levels. In a report issued on April 10, Raymond James also initiated coverage with a Buy rating on the stock with a $104.00 price target.
Read More on ABT:
